USSTOCK.TODAY
Pre-Market
Log in Sign up

Eli Lilly and Novo Nordisk Compete for GLP-1 Market Dominance

Nasdaq +1 · ·by G4L

NVO Novo Nordisk ADR
$40.70 -1.64%
View chart & analysis →
  1. 1Eli Lilly has recorded a value increase of over 50% over the past 12 months.
  2. 2Eli Lilly achieved a revenue growth rate of 39% based on recent quarterly results.
  3. 3Novo Nordisk reported 6% revenue growth based on recent quarterly results.

So what's the key point?

Eli Lilly and Novo Nordisk are competing intensely in the obesity treatment market. Eli Lilly showed significant growth with revenue increasing by 39%.

Source Nasdaq +1 · View original ↗

Related 3-line summaries

Palatin Technologies Prepares for Next-Generation Peptide Clinical Trials FinanceWire · yesterdayNovonesis targets supplement market to support GLP-1 users CNBC · yesterdayEli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition The Motley Fool +7 · yesterday
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news